We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+25.24%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$901M
AUM Growth
-$110M
Cap. Flow
-$189M
Cap. Flow %
-20.99%
Top 10 Hldgs %
74.5%
Holding
49
New
9
Increased
9
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$50.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$23.4M
3
TVTX icon
Travere Therapeutics
TVTX
+$19.8M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$19.7M
5
ZYME icon
Zymeworks
ZYME
+$19.3M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$62.5M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.5M
3
UTHR icon
United Therapeutics
UTHR
+$44.6M
4
ARRY
Array Biopharma Inc
ARRY
+$43.9M
5
PBYI icon
Puma Biotechnology
PBYI
+$34.9M

Sector Composition

Rank Sector Weight
1 Healthcare 89.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$1.82B
$129M 14.32%
5,260,803
-306,545
-6% -$4.62M
PTCT icon
2
PTC Therapeutics
PTCT
$5.64B
$88.8M 9.86%
1,974,385
+160,125
+9% +$6.32M
ZGNX
3
DELISTED
Zogenix, Inc.
ZGNX
$76.1M 8.45%
1,593,396
+393,851
+33% +$15.9M
BOLD
4
DELISTED
Audentes Therapeutics, Inc
BOLD
$72.8M 8.08%
1,922,937
+350,319
+22% +$13.5M
KURA icon
5
Kura Oncology
KURA
$800M
$60M 6.66%
3,047,800
+402,700
+15% +$6.68M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$59.5M 6.61%
1,449,300
+369,187
+34% +$15.3M
ASND icon
7
Ascendis Pharma A/S
ASND
$16B
$57.6M 6.39%
500,000
+85,000
+20% +$10.2M
TCDA
8
DELISTED
Tricida, Inc. Common Stock
TCDA
$56.2M 6.24%
+1,423,998
New +$50.1M
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.43B
$40.1M 4.45%
1,500,000
-500,000
-25% -$12.8M
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$30.9M 3.43%
+300,000
New +$23.4M
MRTX
11
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$30.9M 3.43%
+300,000
New +$23.4M
ZYME icon
12
Zymeworks
ZYME
$1.61B
$23.4M 2.6%
1,064,041
+1,049,431
+7,183% +$19.3M
TVTX icon
13
Travere Therapeutics
TVTX
$5.2B
$20.2M 2.24%
+1,003,600
New +$19.8M
MRTX
14
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18M 2%
+175,000
New +$13.6M
PRTA icon
15
Prothena Corp
PRTA
$425M
$17.7M 1.97%
+1,676,250
New +$17.2M
BHVN
16
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$15.3M 1.7%
+350,000
New +$19.7M
TPST icon
17
Tempest Therapeutics
TPST
$13.7M
$14.9M 1.65%
6,606
– –
DERM
18
DELISTED
Dermira, Inc.
DERM
$14.8M 1.65%
1,552,900
+52,900
+4% +$570K
ZGNX
19
PUT
DELISTED
Zogenix, Inc.
ZGNX
$14.3M 1.59%
+300,000
New +$12.1M
GNFT
20
DELISTED
Genfit
GNFT
$13.7M 1.52%
694,253
-536,061
-44% -$12.5M
YARW
21
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$10.4M 1.15%
482
-89
-16% -$2.2M
BHVN
22
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.76M 0.97%
200,000
– –
FOMX
23
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.02M 0.56%
2,110,071
-587,062
-22% -$1.75M
IOVA icon
24
CALL
Iovance Biotherapeutics
IOVA
$1.82B
$4.9M 0.54%
+200,000
New +$3.01M
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.26M 0.47%
342,064
+32,500
+10% +$432K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Great Point Partners held 49 positions worth $901M, down 11% from $1.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Great Point Partners withdrew a net $189M in Q2 2019, closing 19 positions and reducing 8 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $62.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Tricida, Inc. Common Stock worth $56.2M.

  • Great Point Partners's largest Q2 2019 buy was Tricida, Inc. Common Stock: 1,423,998 shares worth $56.2M.
  • Great Point Partners added most to Zymeworks in Q2 2019, an estimated $19.3M increase.
  • Great Point Partners's biggest Q2 2019 reduction was Five Prime Therapeutics, Inc., cutting an estimated $17.7M.
  • Great Point Partners fully exited Global Blood Therapeutics, Inc. in Q2 2019, selling an estimated $62.5M.
  • Great Point Partners's ten largest holdings make up 74% of its $901M portfolio in Q2 2019.
  • Great Point Partners opened 9 new positions and closed 19 in Q2 2019.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $901M.

Based on Great Point Partners's 13F filing for Q2 2019, filed 14 Aug 2019.